Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women

  • Technology appraisal guidance
  • TA160
  • Published: 
  • Last updated: 
Download guidance (PDF)

6 Recommendations for further research

6.1

Given the evidence that the benefits of 1 of the bisphosphonates (alendronate) may continue for several years after the end of treatment, the Committee recommends that research should be carried out to define the optimal duration of treatment with individual bisphosphonates.

6.2

The Committee recommends research into the long-term effects of bisphosphonates on bone quality, given the inhibitory effects on bone resorption of these drugs.